新闻
HEPA
--
0.00%
--
Hepion Pharma announces clinical collaboration with HepQuant for a phase 2b NASH trial
Hepion Pharmaceuticals (NASDAQ:HEPA) on Tuesday entered into a clinical collaboration with Denver, Colo.-based HepQuant, a privately held company with investigational technology for evaluating liver function and health in patients with
Seekingalpha · 05/03 13:54
BRIEF-Hepion Pharmaceuticals Announces Clinical Collaboration With HepQuant In Phase 2B NASH Trial
reuters.com · 05/03 12:31
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes - - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat - - Four-Month, Three Arm Trial will Inform on Numerous NASH Funct...
GlobeNewswire · 05/03 12:00
Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference
EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatoh...
GlobeNewswire · 03/07 13:00
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades
Benzinga · 02/28 15:27
--Cantor Fitzgerald Starts Hepion Pharmaceuticals at Overweight With $3.50 Price Target
MT Newswires · 02/28 07:50
Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference
EDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohe...
GlobeNewswire · 02/14 13:00
Hepion's Rencofilstat Combo Shows Anti-Tumor Activity In Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced the results of a nonclinical research study showing rencofilstat (CRV431) 
Benzinga · 01/26 16:20
Hepion's rencofilstat combo reduces tumor growth in nonclinical liver cancer study
Hepion Pharmaceuticals (NASDAQ:HEPA) said the results of a nonclinical research study showed that its drug candidate, rencofilstat (CRV431) decreased liver tumor growth and extended mouse survival when combined with an
Seekingalpha · 01/26 14:34
Hepion Pharmaceuticals' Rencofilstat, In Combination With An Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity In A Nonclinical Liver Cancer Study
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic
Benzinga · 01/26 13:09
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancerEDISON, N.J., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage ...
GlobeNewswire · 01/26 13:00
Hepion Says Rencofilstat Plus Antibody Decreased Liver Cancer Growth in Nonclinical Study of Mice; Shares Rise
MT Newswires · 01/26 09:43
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 01/07 12:34
BRIEF-Hepion Pharmaceuticals Announces USAN Selection Of "Rencofilstat" As Nonproprietary Name For CRV431
reuters.com · 01/06 22:34
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference
- Oral Presentation Chosen as a “Distinguished” Abstract -EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic dr...
GlobeNewswire · 01/05 13:30
FDA clears Hepion Pharma's CRV431 application for liver cancer
Hepion Pharmaceuticals (NASDAQ:HEPA) announces that the FDA has accepted its investigational new drug (IND) application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Shares up
Seekingalpha · 2021/12/21 13:51
BRIEF-Hepion Pharmaceuticals Announces FDA Clearance Of Ind Application For CRV431 In The Treatment Of Liver Cancer
reuters.com · 2021/12/21 13:06
Hepion Pharmaceuticals gets FDA fast track designation for CRV431 to treat liver disease
The U.S. Food and Drug Administration granted fast track designation to Hepion Pharmaceuticals (HEPA) lead drug candidate CRV431 to treat non-alcoholic steatohepatitis (NASH), a type of liver disease. “CRV431 has been
Seekingalpha · 2021/11/30 13:56
VIR, HEPA and POLA among pre market gainers
Cumberland Pharmaceuticals CPIX +90% on FDA label expansion for pain therapy Pioneer Power Solutions (NASDAQ:PPSI) +66%. First Wave BioPharma (NASDAQ:FWBI) +53% announces independent data monitoring committee provides positive interim safety assessment for...
Seekingalpha · 2021/11/30 13:28
Hepion Pharmaceuticals Receives FDA Fast Track Designation For CRV431 For The Treatment Of NASH
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic
Benzinga · 2021/11/30 13:08
微牛提供丰富的实时HEPA股票新闻,让你可以通过多个平台了解HEPA股票行情最新动态,这些免费的Hepion制药新闻可以帮助你做出明智投资。
HEPA 简况
Hepion Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发治疗慢性肝病的药物疗法。这种治疗方法针对与非酒精性脂肪性肝炎(NASH)、病毒性肝炎和其他肝脏疾病相关的纤维化和肝细胞癌(HCC)。该公司的亲环蛋白抑制剂CRV431有利于解决这些多种复杂的病理。CRV431是一种泛环亲环蛋白抑制剂,靶向涉及肝病发展过程的多种病理途径。该公司创建了一个名为AI-POWR的人工智能平台,代表人工智能精准医学组学世界数据库访问和响应以及临床结果。该平台有助于确定哪些NASH患者对CRV431反应最好,从而可能缩短开发时间并增加安慰剂组和治疗组之间的差异性。